Skip to content

To assess the safety and outcome of herbal medicine in prevention of COVID-19 infection among high risk population

A Prospective Cohort Interventional Study Assessing the Safety and Outcome of Unani Medicine as a Prophylaxis in Population at risk of COVID-19

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025650
Enrollment
4000
Registered
2020-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Joshanda (Decoction) and Khameera Marwareed: Joshanda (Decoction) of the following 1. Behidana (Cydonia oblonga) 3 gm 2. Unnab (Zizyphus jujube) 5 in number 3. Sapistan (Cordia myxa)

Sponsors

Ministry of AYUSH Government of India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Population as described in High/Moderate/Low Risk 2. Individuals who are from the identified containment zone/ quarantine facility with at least 1 confirmed COVID-19 positive case. 3. Subjects who are ready to provide written/digital informed consent and who are willing to participate and follow the protocol requirements of the clinical study

Exclusion criteria

Exclusion criteria: 1. Persons with severe primary respiratory disease or related complications that may be identified with COVID-19 2. Laboratory confirmed COVID-19 with or without symptoms 3. Pregnant and lactating mothers and those who have a pregnancy plan. 4. Persons with serious critical illness, or severe mental illnesses 5. Individuals with uncontrolled, unstable co-morbidities 6. Immuno-compromised individuals or those on immune-suppressants and steroids 7. Subjects having a past history of allergy to any medicine that is part of the Unani intervention

Design outcomes

Primary

MeasureTime frame
1. Incidence of COVID-19 cases in control as well in interventional group 2. Improvement in immune status using Immune Status Questionnaire (ISQ)Timepoint: 0th Day, 10th Day, 20th Day and 35th Day

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactProf Abdul Wadud

National Institute of Unani Medicine

drwadud87@gmail.com9916608881

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026